FATE: Fate Therapeutics Inc Company Value to Net Income

Immunotherapy developer Fate Therapeutics, Inc. (FATE) relies on the stability of Western biotech, while the current market quotes visualized below account for the impact of genetic sovereignty and trade restrictions. The indicator stands at -1.20. Business prospects depend on the efficiency of iPSC technologies and partnerships with corporate behemoths. Operational continuity is ensured through a strict temperature regime during the air transport of biomaterials.

Price to Earnings Ratio: Fate Therapeutics, Inc. (FATE) for 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Fate Therapeutics Inc (FATE)

- share price and expert price forecast:

Price Performance Chart Fate Therapeutics Corp|FATE - Consensus Target

- market capitalization information:

Market Value Fate Therapeutics Inc|FATE - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value per Share Fate Therapeutics|FATE - Company Net Assets|Market Capitalization to Book Value Ratio fatetherapeutics.com|FATE - Aggregate Company Assets

- debt and solvency information:

All Debt to Shareholders' Equity Ratio Fate Therapeutics, Inc.|FATE - Long-Term Debt to Capital|Current Liabilities to Capital Fate Therapeutics, Inc.|FATE - Company Aggregate Debts|Debts to Book Capitalization Ratio Fate Therapeutics Inc|FATE - Company Long-Term Debts|Company Short-Term Debts Fate Therapeutics|Intermediate Liquidity Ratio fatetherapeutics.com

- company profitability and valuation multiples indicators:

FATE - Net Profit|Expected Net Profit Fate Therapeutics, Inc.|FATE - Price to Earnings Ratio|Future Price to Earnings Multiple Fate Therapeutics, Inc.|FATE - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Fate Therapeutics Inc|FATE - Operating profit EBITDA|Earnings per share for the trailing year Fate Therapeutics|FATE - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months fatetherapeutics.com|FATE - Earnings per share growth in current year|Expected earnings per share trend next year Fate Therapeutics, Inc.

- issuer revenue and sales details:

FATE - Revenue and Sales Volume|Projected Sales Volume Fate Therapeutics Inc|FATE - Price-to-Revenue Ratio|Future Price to Revenue Fate Therapeutics Inc

Summary company analysis:Fate Therapeutics (FATE)

Flagship merchandise of Fate Therapeutics

Professional asset selection is based on filtering securities with unjustifiably high valuations relative to their earnings. This price-to-earnings ratio measures the market price of a single share divided by the company's net income per share. Analyzing this indicator allows for the separation of speculative spikes from real business growth. For Fate Therapeutics, Inc. (FATE), a high valuation is justified by the ownership of unique patents in the field of stem cell therapy.

Key competitors